CSIMarket Company Name, Ticker, Industry, else..
 
Crescent Biopharma Inc   (NASDAQ: CBIO)
 
Price: $16.5200 $-0.66 -3.842%
Day's High: $18.565000534057617 Week Perf: -14.89 %
Day's Low: $ 16.44 30 Day Perf: -1.02 %
Volume (M): 260,799 52 Wk High: $ 27.41
Volume (M$): $ 0 52 Wk Avg: $15.05
Open: $17.60 52 Wk Low: $8.72



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 44
 Revenues (TTM) (Millions $) 14
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -107
 Capital Exp. (TTM) (Millions $) 9

Business Description


The company is a clinical-stage biotechnology firm developing cancer therapies. Its main programs include CR-001, a PD-1 x VEGF bispecific antibody, and a portfolio of antibody drug conjugates (ADCs) including CR-002 and CR-003. The company is conducting clinical trials for these therapies and has partnered with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for their global development and commercialization.


   Company Address: 300 Fifth Avenue Waltham 2451 MA
   Company Phone Number: 430-5595   Stock Exchange / Ticker: NASDAQ CBIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AGIO        0.04% 
GALT   -4.74%    
LTRN        2.27% 
PHAT   -7.95%    
SNDX   -5.26%    
URGN        2.49% 
• View Complete Report
   



Clinical Study

Crescent Biopharmas Innovative CR-001 A Forward Leap in Cancer Immunotherapy,

Published Tue, Nov 4 2025 10:03 PM UTC

Crescent Biopharma s CR-001: A Promising New Approach in Cancer Immunotherapy In the evolving landscape of cancer immunotherapy, Crescent Biopharma Inc. has made a notable advancement with their investigational bispecific antibody, CR-001. The company is set to present compelling preclinical data at the 40th Annual Meeting of the Society for Immunotherapy of Cancers (SITC), ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 9.26
Working Capital Ratio 9.66
Leverage Ratio (MRQ) 0.12
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -192.32 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 310,295
Net Income per Employee (TTM) -201,819
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.07

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -1489.49 %
Net Margin (MRQ) -1281.86 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.